Alzheimer's Disease: The Biology Behind the Decline
Photo: www.kaboompics.com / Pexels
Alzheimer's disease is the most common cause of dementia, accounting for 60–80% of all cases worldwide. Approximately 55 million people currently live with dementia globally, and that number is projected to triple by 2050 as populations age. Yet for most of the twentieth century, the disease remained a black box — a slow erasure of self whose molecular causes were almost entirely unknown.
Educational content, not medical advice. Talk to your doctor before changing any medication, treatment, or routine. Information here reflects current research but every person's situation differs.
Today, the picture is far clearer. Decades of research have produced a detailed — if still contested — account of how abnormal protein aggregates accumulate in the brain, damage synapses, and Eventually, kill neurons. New biomarker tools can detect the disease 20 years before a patient forgets a single name. And two drugs approved by the FDA in 2023 have, for the first time, demonstrably slowed its progression. This article traces the biology from first molecular event to final clinical stage, and examines what the latest science means for prevention and treatment.
The Amyloid Hypothesis: The Central Theory
In 2002, John Hardy and Dennis Selkoe published a landmark synthesis in Science that crystallized what had been building in the field for over a decade: the amyloid cascade hypothesis. The core claim is that the abnormal accumulation of amyloid-beta (Aβ) peptide is the initiating event in Alzheimer's disease, upstream of all other pathology.
Amyloid-beta is a peptide normally cleaved from amyloid precursor protein (APP) by enzymes called secretases. In most people, these fragments are cleared efficiently. In Alzheimer's, either overproduction (as in familial early-onset cases with APP or presenilin gene mutations) or impaired clearance causes Aβ to accumulate and misfold into oligomers — small, soluble clumps that are highly toxic to synapses — and eventually into the insoluble amyloid plaques visible in postmortem brain tissue.
The hypothesis predicts a cascade: amyloid accumulation triggers downstream tau pathology, which triggers neuronal death. This sequence has gained strong support from genetic evidence. Every inherited form of early-onset Alzheimer's involves mutations that increase Aβ42 (the more aggregation-prone variant) or the Aβ42/Aβ40 ratio. People with Down syndrome (trisomy 21, which carries an extra copy of the APP gene) almost universally develop Alzheimer's pathology by their 40s. The strongest genetic risk factor in late-onset disease, the APOE4 allele, encodes a protein that is inefficient at clearing amyloid from the brain.
Tau Tangles: The Second Blow
While amyloid may pull the trigger, tau neurofibrillary tangles are closely linked to the neuronal death that produces symptoms. Tau is a microtubule-associated protein that normally stabilizes the internal scaffolding of neurons. In Alzheimer's, tau becomes hyperphosphorylated — decorated with far more phosphate groups than normal — causing it to detach from microtubules and aggregate into twisted filaments called paired helical filaments, which accumulate as neurofibrillary tangles inside neurons.
The result is catastrophic for the cell. Without functional microtubules, axonal transport breaks down: nutrients, organelles, and signaling molecules cannot reach synapses. The neuron becomes dysfunctional and eventually dies.
Critically, tau pathology appears to spread through the brain in a prion-like manner. Misfolded tau seeds can be taken up by neighboring neurons, templating the misfolding of normal tau within each new host cell. Heiko Braak's staging system — which ranks Alzheimer's severity by the anatomical spread of tau tangles — maps this progression with remarkable consistency across patients. Tangles begin in the entorhinal cortex and hippocampus (Braak stages I–II), spread to association cortices (stages III–IV), and eventually reach primary cortices (stages V–VI). This progression maps almost perfectly onto the clinical symptoms patients experience.
Alzheimer's as a Continuum: Biomarkers Before Symptoms
One of the most important conceptual shifts in modern Alzheimer's research came from Clifford Jack and colleagues in a 2010 Lancet Neurology paper that reconceptualized the disease as a biological continuum — a decades-long process that begins with molecular changes long before any cognitive symptom appears.
Jack's biomarker model proposes a sequence: amyloid accumulates first, becoming detectable by amyloid PET imaging or reduced CSF Aβ42 levels (amyloid is sequestered in plaques and falls in the fluid). Tau pathology follows, detectable by CSF phosphorylated-tau (p-tau) levels and eventually tau PET. Neurodegeneration — measured by FDG-PET hypometabolism, atrophy on MRI, or rising neurofilament light chain (NfL) in blood — comes next. Only then do cognitive symptoms emerge.
The gap between first biomarker change and first symptom is estimated at 15–20 years. This has profound implications: by the time a patient walks into a clinic with memory complaints, the disease process is already far advanced.
Recent years have seen a revolution in blood-based biomarkers that could make earlier detection accessible at scale. Plasma p-tau 217 has emerged as particularly powerful. Studies published in 2023–2024 show that plasma p-tau 217 can distinguish Alzheimer's from other dementias with accuracy rivaling CSF or PET — at a fraction of the cost and without a lumbar puncture. This biomarker tracks amyloid load in the brain with remarkable fidelity and rises years before symptoms, opening the door to population-level screening.
The Disease Stages: From Forgetting Names to Losing Self
Alzheimer's clinical progression follows a relatively predictable anatomical logic, driven by the spread of tau pathology described above.
Early stage (mild): The hippocampus — critical for forming new episodic memories — is among the first structures affected. Patients notice difficulty remembering recent events, repeating questions, or misplacing objects. Word-finding problems begin. Day-to-day function is largely preserved. Many patients are aware of their deficits, which often causes anxiety and depression.
Middle stage (moderate): Pathology spreads to lateral temporal, parietal, and frontal association cortices. Language deteriorates more severely (aphasia), spatial navigation fails, and executive function — planning, judgment, multitasking — collapses. Patients may no longer recognize family members and require assistance with daily activities. Behavioral symptoms (agitation, sleep disruption, wandering) become prominent.
Late stage (severe): Widespread cortical involvement eventually reaches primary motor cortices. Patients lose the ability to walk, speak coherently, or swallow. They become entirely dependent on care. Death usually results from complications of immobility — pneumonia, urinary tract infections, pressure ulcers — typically 8–10 years after diagnosis (though the range is wide: 3–20 years).
Risk Factors: What Increases Vulnerability?
Age is the single strongest risk factor. The prevalence of Alzheimer's doubles roughly every five years after age 65, affecting about 10% of people over 65 and nearly one-third of those over 85.
APOE4 is the most significant genetic risk factor for late-onset Alzheimer's. Carrying one copy (heterozygote) increases risk 3–4 fold relative to APOE3 homozygotes. Carrying two copies (homozygote) increases risk 8–12 fold. APOE4 appears to impair amyloid clearance, accelerate plaque formation, and compromise the blood-brain barrier.
Modifiable risk factors now account for an estimated 40% of dementia cases according to the 2024 Lancet Commission update. Key modifiable factors include:
- Sleep disruption: Insufficient or poor-quality sleep impairs glymphatic clearance of amyloid (see below), and chronically elevated Aβ levels further disrupt sleep — a vicious cycle.
- Cardiovascular health: Hypertension, diabetes, obesity, and physical inactivity each independently increase risk.
- Cognitive reserve: Higher education, bilingualism, and mentally demanding occupations are associated with later symptom onset, likely because they increase synaptic density and network redundancy.
- Hearing loss: Now recognized as the largest single modifiable risk factor, possibly because it accelerates social isolation and cognitive disengagement.
- Head trauma: Repeated traumatic brain injury is a significant risk factor.
Dementia Types: Where Alzheimer's Fits
Not all dementia is Alzheimer's. The table below summarizes the major types and their distinguishing features.
| Type | % of Dementia Cases | Key Pathology | Earliest Symptom | Distinguishing Feature |
|---|---|---|---|---|
| Alzheimer's disease | 60–80% | Amyloid plaques + tau tangles | Episodic memory loss | Hippocampal atrophy; slow progression |
| Vascular dementia | 10–15% | Cerebrovascular lesions | Variable (executive dysfunction common) | Step-wise decline; stroke history |
| Lewy body dementia | 5–10% | Alpha-synuclein Lewy bodies | Visual hallucinations, REM sleep disorder | Fluctuating cognition; Parkinsonism |
| Frontotemporal dementia | 5–10% | TDP-43 or tau (Pick bodies) | Personality/behavior change | Frontal/temporal atrophy; younger onset (50s–60s) |
| Mixed dementia | ~10% | Combination (often AD + vascular) | Variable | Common in very elderly |
Sleep and the Glymphatic System
One of the most striking recent discoveries in Alzheimer's research concerns sleep. In 2013, Maiken Nedergaard and colleagues published a Science paper showing that the brain has a dedicated waste-clearance system — the glymphatic system — that is largely active during sleep. Cerebrospinal fluid is pumped through perivascular spaces surrounding brain arteries, flushing interstitial waste (including amyloid-beta) into venous drainage.
The glymphatic system is 10-fold more active during sleep than waking. In animal models, sleep deprivation causes amyloid to accumulate in the interstitium within hours. Human studies using PET imaging have confirmed that even one night of sleep deprivation measurably increases amyloid burden in the brain.
The implications are sobering. Sleep disorders — particularly obstructive sleep apnea, which disrupts sleep architecture and reduces slow-wave sleep — are strongly associated with elevated amyloid on PET and accelerated cognitive decline. The relationship is bidirectional: amyloid itself disrupts sleep by damaging the basal forebrain neurons that regulate slow-wave sleep. This positive-feedback loop may be an important driver of disease acceleration in the middle stages.
The Viral Connection: Herpesviruses in the Brain
A provocative line of research has implicated common herpesviruses in Alzheimer's pathology. In 2018, Readhead and colleagues published a large genomic analysis of postmortem brain tissue showing that herpesvirus sequences — particularly HHV-6A and HHV-7 — were significantly enriched in Alzheimer's brains compared to controls, and that viral genes were integrated into networks regulating amyloid and tau processing.
Earlier work had associated HSV-1 (the cold sore virus) with Alzheimer's risk, particularly in APOE4 carriers. The proposed mechanism is that viral reactivation in the brain triggers amyloid deposition as an innate immune response — Aβ may function as an antimicrobial peptide that traps pathogens in aggregates. This "antimicrobial protection hypothesis," advanced by Robert Moir and Rudolph Tanzi, offers an alternative framing: plaques may begin as a defensive response that becomes pathological.
This hypothesis remains controversial and has not been replicated with the consistency needed for clinical translation. But it has spurred interest in antiviral approaches — preliminary data from a large Taiwanese cohort showed that individuals treated with antiherpetic drugs had significantly lower rates of dementia.
New Drugs: Lecanemab and Donanemab
For decades, amyloid-clearing drugs failed in clinical trials. The field debated whether this meant the amyloid hypothesis was wrong, or whether drugs were given too late. Recent trials have provided a partial answer.
Lecanemab (Leqembi), developed by Eisai and Biogen, is a monoclonal antibody that targets amyloid protofibrils — soluble oligomers believed to be the most synaptotoxic form. In the CLARITY AD phase 3 trial (NEJM, 2023), lecanemab reduced amyloid burden on PET and slowed decline on the CDR-SB (Clinical Dementia Rating Sum of Boxes) scale by 27% over 18 months compared to placebo. The FDA granted full approval in July 2023. The drug is given by IV infusion every two weeks and requires amyloid confirmation before initiation.
Donanemab (Eli Lilly), which targets a post-translationally modified form of plaque amyloid, showed 35% slowing of decline on the iADRS scale in the TRAILBLAZER-ALZ 2 trial (JAMA, 2023), with the strongest effects in patients with lower baseline tau burden. FDA approval followed in 2024.
Both drugs carry significant risks of amyloid-related imaging abnormalities (ARIA) — microhemorrhages and edema detectable on MRI — which are more common in APOE4 carriers. Careful patient selection and monitoring are required. Critically, both drugs slow but do not stop progression; absolute benefits are modest in clinical terms, and their cost-effectiveness remains debated.
The controversy around the amyloid hypothesis has partly shifted. The question is no longer whether amyloid is involved — two drugs that clear amyloid do slow the disease. The question is whether oligomers rather than plaques are the true culprit (plaques may be a relatively inert sink), and whether hitting amyloid alone is sufficient or whether tau and neuroinflammation must also be targeted.
Future Treatments: Beyond Amyloid
The pipeline has expanded considerably beyond amyloid.
Tau-targeting therapies include anti-tau monoclonal antibodies (several in phase 2/3 trials), tau aggregation inhibitors, and antisense oligonucleotides that reduce tau expression. Given that tau burden correlates more directly with cognitive symptoms than amyloid, tau-targeting may produce larger clinical benefits — particularly in later-stage patients.
Neuroinflammation has emerged as a third major pathway. Microglia — the brain's resident immune cells — play complex roles in Alzheimer's, clearing debris but also releasing inflammatory cytokines that damage neurons. TREM2 variants increase Alzheimer's risk and impair microglial amyloid clearance. Multiple TREM2-activating antibodies are in early trials.
BACE inhibitor failures taught the field a hard lesson: verubecestat, lanabecestat, and other inhibitors of the beta-secretase that generates Aβ produced cognitive worsening in trials, possibly because BACE1 has many substrates beyond APP. The enzyme may be too important to inhibit broadly.
Gene therapy for APOE4 carriers is an active area: clinical trials are under way to deliver the APOE2 allele (protective) or APOE3 to the brain via AAV vectors, aiming to shift amyloid clearance capacity. Early safety data are encouraging.
Prevention: What the Evidence Supports
Given the 20-year biological window before symptoms, prevention is scientifically plausible. The strongest evidence currently supports:
- Aerobic exercise: Consistently associated with reduced risk (30–40% in observational data) and with reduced amyloid accumulation and hippocampal volume preservation in intervention trials.
- Sleep quality: Treating obstructive sleep apnea reduces biomarker burden in small trials.
- Cardiovascular risk management: Blood pressure control in midlife reduces late-life dementia risk.
- Hearing aids: Observational data suggest hearing loss treatment reduces cognitive decline risk, with a randomized trial (ACHIEVE, 2023) showing benefit in high-risk individuals.
- Social engagement and cognitive stimulation: Associated with reduced risk, though randomized trial data are less robust.
No single intervention has been proven in a large randomized trial to prevent Alzheimer's in the general population. But the Lancet Commission's estimate that 40% of dementia is attributable to modifiable risk factors provides a strong public health rationale for lifestyle optimization — independent of any pharmaceutical breakthrough.
Frequently Asked Questions
Q: What is the difference between Alzheimer's disease and dementia? A: Dementia is an umbrella term for a syndrome of cognitive decline severe enough to interfere with daily life. Alzheimer's disease is the most common cause of dementia, responsible for 60–80% of cases. Other causes include vascular dementia, Lewy body dementia, and frontotemporal dementia.
Q: Can Alzheimer's be detected before symptoms appear? A: Yes. Amyloid PET imaging, CSF biomarkers (Aβ42, p-tau), and newer blood tests such as plasma p-tau 217 can detect biological signs of Alzheimer's 15–20 years before cognitive symptoms emerge, as outlined in Jack et al.'s 2010 Lancet staging model.
Q: What does the APOE4 gene actually do to increase risk? A: APOE4 encodes an apolipoprotein that is less efficient than APOE2 or APOE3 at binding and transporting amyloid-beta for clearance. Carriers accumulate amyloid more rapidly, develop plaques at younger ages, and face 3–12x higher lifetime risk depending on whether they carry one or two copies.
Q: How do lecanemab and donanemab work? A: Both are monoclonal antibodies that bind to specific forms of amyloid-beta and recruit the immune system to clear it from the brain. Lecanemab targets protofibrils (soluble oligomers); donanemab targets pyroglutamate-modified plaque amyloid. Both reduce amyloid burden on PET and modestly slow clinical decline in early-stage patients.
Q: Why did so many Alzheimer's drugs fail before lecanemab? A: Several reasons: many trials enrolled patients too late (when neuronal death was already extensive), some drugs had poor brain penetrance, BACE inhibitors had off-target effects, and anti-amyloid antibodies used in earlier trials (like bapineuzumab) may not have targeted the most toxic amyloid species.
Q: What is the glymphatic system and how does it relate to Alzheimer's? A: The glymphatic system is a waste-clearance network that uses cerebrospinal fluid flow through perivascular spaces to flush metabolic waste — including amyloid-beta — from the brain. It is most active during deep (slow-wave) sleep. Chronic sleep disruption impairs this clearance and allows amyloid to accumulate, which in turn further disrupts sleep architecture.
Q: Is Alzheimer's linked to viral infections? A: This remains an active area of research. A 2018 genomic study (Readhead et al.) found enrichment of HHV-6A and HHV-7 sequences in Alzheimer's brains. HSV-1 has also been linked to increased risk, particularly in APOE4 carriers. One proposed mechanism is that amyloid-beta functions as an antimicrobial peptide that traps viruses, with the aggregates becoming pathological over time. Evidence is suggestive but not yet conclusive.
Q: Can lifestyle changes really prevent Alzheimer's? A: They can reduce risk significantly. The 2024 Lancet Commission estimates that approximately 40% of dementia cases are attributable to 14 modifiable risk factors, including physical inactivity, hypertension, hearing loss, depression, smoking, diabetes, obesity, and low education. No intervention has been proven in a large randomized trial to fully prevent Alzheimer's, but aerobic exercise, cardiovascular risk control, and hearing loss treatment have the strongest evidence bases.
Internal Resources
For broader context on how neurons communicate and degenerate, see ./how-neurons-communicate. The genetics of aging and why cells accumulate damage over time is explored in ./biology-of-aging-explained. For a deeper look at how the immune system interacts with the nervous system — relevant to neuroinflammation in Alzheimer's — see ./neuroinflammation-and-the-brain. The biology of sleep and why deep sleep is essential for brain function is covered in ./sleep-science-why-we-sleep.
Key Sources
- Hardy J, Selkoe DJ. "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics." Science. 2002;297(5580):353–356.
- Jack CR Jr, et al. "Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade." Lancet Neurology. 2010;9(1):119–128.
- van Dyck CH, et al. "Lecanemab in Early Alzheimer's Disease." New England Journal of Medicine. 2023;388(1):9–21.
- Sims JR, et al. "Donanemab in Early Symptomatic Alzheimer's Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial." JAMA. 2023;330(6):512–527.
- Xie L, et al. "Sleep Drives Metabolite Clearance from the Adult Brain." Science. 2013;342(6156):373–377.
- Readhead B, et al. "Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus." Neuron. 2018;99(1):64–82.
- Livingston G, et al. "Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission." Lancet. 2024;404(10452):572–628.
- Braak H, Braak E. "Neuropathological staging of Alzheimer-related changes." Acta Neuropathologica. 1991;82(4):239–259.
Read next:
Follow new articles
Add SciHub101 to your feed reader to see new science and technology stories.
About the Author
SciHub101 is an independent science and technology publication founded and edited by Buğra Sözeri, a software engineer and app developer based in Türkiye. AI tools assist with drafting and research. Source documentation in the existing archive is uneven, and articles are being reviewed and corrected. The Editorial Team byline identifies editorial responsibility; it does not certify specialist or independent human review. Where we compare products, anything built by our own team is labelled as such — see the editorial guidelines and About page for how corrections and disclosures work.
Related Articles
The Immune System: How It Works Explained
Explore how the immune system defends your body — from skin barriers to T cells, vaccines, autoimmunity, and cancer immunotherapy.
Depression: The Neuroscience Behind It
Depression is more than low serotonin. A look at the brain biology behind it: the serotonin debate, stress hormones, inflammation, neuroplasticity and new treatments.
Alzheimer's Disease in 2026 — What We Know, Can Treat, and Still Can't
Leqembi and Kisunla slow Alzheimer's progression by 27–35%. Here's what science finally knows about amyloid, tau, blood biomarkers, and the 14 modifiable risk factors.
Why Time Feels Faster as You Age: The Science Behind It
A summer at age eight felt endless. A year at forty disappears. This is not nostalgia distorting judgment — it is a measurable difference in how the brain processes and encodes time. Multiple mechanisms are involved: a mathematical relationship between age and perceived duration, a decline in the novelty that creates dense memories, slowing neural processing speed, and falling dopamine levels that alter the brain's internal clock. Each mechanism operates independently, but they all converge on the same result: subjective time accelerates across a human lifetime.
The Science of Sleep: What Happens in the Brain During REM Sleep
Sleep is not a passive shutdown but an active state of brain and body reorganization. During an 8-hour sleep cycle, humans alternate between non-REM (NREM) sleep—characterized by slow theta waves, reduced muscle tone, and energy conservation—and REM (rapid eye movement) sleep, when the brain shows activity patterns similar to wakefulness, the eyes move rapidly beneath closed eyelids, and skeletal muscles are paralyzed except for the diaphragm. REM sleep makes up approximately 20–25 percent of sleep in adults and is the stage where most vivid dreaming occurs. The neuroscience of REM reveals that memory consolidation (particularly emotional and procedural memories), creativity processing, and amygdala-driven emotion regulation all occur during this stage. The glymphatic system—a network of fluid pathways that clear metabolic waste from the brain during sleep—becomes most active during deep NREM sleep, not REM. This article explains the neuroscience of REM sleep, the discovery of the glymphatic system, and why sleep is essential to brain health.
What Happens to Your Body with No Sleep for 24 to 72 Hours
After 17 hours without sleep, your cognitive performance matches someone with a blood alcohol concentration of 0.05% — legally impaired to drive in most countries. After 24 hours, the equivalent is 0.10% — above the legal limit in all US states. After 72 hours, hallucinations are common, emotional regulation breaks down, and the immune system's ability to mount a response is measurably compromised. Sleep deprivation is not discomfort — it is a physiological insult to nearly every system in the body, and it unfolds on a precisely documented timeline.